ALB and hepatocellular carcinoma: Conversely, higher platelet count (aHR 0.62, 95% CI: 0.47–0.82; p = 0.001), higher serum albumin (aHR 0.64, 95% CI: 0.48–0.86; p = 0.003), and DLP with statin use (aHR 0.43, 95% CI: 0.22–0.85; p = 0.015) were significantly associated with reduced HCC risk.